 Amy Feldman
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 23 | 2025 | 833 | 5.530 |
Why?
| | Organ Transplantation | 13 | 2024 | 228 | 4.870 |
Why?
| | Vaccination | 14 | 2025 | 1348 | 3.710 |
Why?
| | Biliary Atresia | 11 | 2025 | 161 | 3.240 |
Why?
| | Cholestasis | 8 | 2025 | 231 | 2.630 |
Why?
| | Transplant Recipients | 11 | 2024 | 163 | 2.550 |
Why?
| | Immunization | 5 | 2023 | 410 | 1.740 |
Why?
| | Vaccines | 6 | 2023 | 400 | 1.720 |
Why?
| | Viral Vaccines | 2 | 2025 | 95 | 1.660 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 66 | 1.280 |
Why?
| | Infant, Newborn, Diseases | 2 | 2021 | 111 | 1.280 |
Why?
| | Pediatrics | 4 | 2024 | 1068 | 1.090 |
Why?
| | Vaccines, Attenuated | 3 | 2025 | 125 | 1.090 |
Why?
| | Child | 35 | 2025 | 20932 | 1.050 |
Why?
| | Communicable Diseases | 2 | 2019 | 152 | 1.000 |
Why?
| | Immunocompromised Host | 4 | 2020 | 199 | 0.950 |
Why?
| | Living Donors | 6 | 2025 | 286 | 0.880 |
Why?
| | Liver Diseases | 3 | 2022 | 291 | 0.870 |
Why?
| | Rubella | 1 | 2023 | 23 | 0.840 |
Why?
| | Mumps | 1 | 2023 | 24 | 0.830 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 858 | 0.820 |
Why?
| | Measles | 1 | 2023 | 44 | 0.810 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 17 | 0.810 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1257 | 0.800 |
Why?
| | Chickenpox | 1 | 2023 | 80 | 0.800 |
Why?
| | Mobile Applications | 1 | 2025 | 166 | 0.780 |
Why?
| | Bilirubin | 2 | 2019 | 95 | 0.730 |
Why?
| | Infant | 15 | 2025 | 9005 | 0.730 |
Why?
| | Transplantation | 1 | 2021 | 31 | 0.720 |
Why?
| | Postoperative Complications | 4 | 2025 | 2475 | 0.680 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 29 | 0.670 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 16 | 0.670 |
Why?
| | Waiting Lists | 2 | 2021 | 237 | 0.670 |
Why?
| | Motor Cortex | 1 | 2020 | 58 | 0.660 |
Why?
| | Neonatal Screening | 2 | 2019 | 163 | 0.660 |
Why?
| | Kidney Transplantation | 2 | 2024 | 669 | 0.660 |
Why?
| | Wrist | 1 | 2020 | 54 | 0.660 |
Why?
| | Hospitalization | 3 | 2019 | 2076 | 0.650 |
Why?
| | Humans | 53 | 2025 | 129527 | 0.650 |
Why?
| | Registries | 8 | 2025 | 1902 | 0.640 |
Why?
| | Cholagogues and Choleretics | 1 | 2019 | 8 | 0.640 |
Why?
| | Oligonucleotides | 1 | 2020 | 145 | 0.630 |
Why?
| | Opportunistic Infections | 1 | 2019 | 46 | 0.630 |
Why?
| | Nutritional Support | 1 | 2019 | 32 | 0.620 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 132 | 0.610 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 761 | 0.610 |
Why?
| | Postoperative Care | 1 | 2020 | 244 | 0.610 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 98 | 0.590 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 98 | 0.590 |
Why?
| | Genetic Therapy | 1 | 2020 | 286 | 0.580 |
Why?
| | Hospital Costs | 1 | 2019 | 115 | 0.580 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 278 | 0.570 |
Why?
| | Child, Preschool | 10 | 2025 | 10499 | 0.560 |
Why?
| | Cross Infection | 1 | 2019 | 219 | 0.530 |
Why?
| | Pyruvic Acid | 1 | 2017 | 53 | 0.530 |
Why?
| | Disease Outbreaks | 1 | 2020 | 349 | 0.520 |
Why?
| | Cytomegalovirus Infections | 2 | 2023 | 190 | 0.520 |
Why?
| | Societies, Medical | 1 | 2020 | 757 | 0.510 |
Why?
| | Immunization Schedule | 1 | 2018 | 197 | 0.510 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 90 | 0.500 |
Why?
| | Graft Rejection | 5 | 2025 | 598 | 0.490 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 120 | 0.480 |
Why?
| | Healthcare Disparities | 1 | 2021 | 579 | 0.480 |
Why?
| | Lactic Acid | 1 | 2017 | 304 | 0.470 |
Why?
| | Graft Survival | 6 | 2025 | 514 | 0.470 |
Why?
| | Adaptive Immunity | 2 | 2015 | 161 | 0.470 |
Why?
| | Health Services Accessibility | 2 | 2021 | 897 | 0.470 |
Why?
| | United States | 9 | 2025 | 13865 | 0.440 |
Why?
| | Gastroenterology | 1 | 2016 | 177 | 0.430 |
Why?
| | Rotavirus | 1 | 2013 | 20 | 0.430 |
Why?
| | Rotavirus Infections | 2 | 2013 | 45 | 0.410 |
Why?
| | Infant, Newborn | 6 | 2025 | 5769 | 0.400 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 5429 | 0.380 |
Why?
| | Reoviridae Infections | 1 | 2012 | 54 | 0.380 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1283 | 0.370 |
Why?
| | Retrospective Studies | 14 | 2025 | 14532 | 0.370 |
Why?
| | Male | 17 | 2025 | 63586 | 0.360 |
Why?
| | Treatment Outcome | 12 | 2025 | 10232 | 0.350 |
Why?
| | Anemia, Aplastic | 2 | 2021 | 36 | 0.350 |
Why?
| | Hepatitis | 2 | 2021 | 47 | 0.350 |
Why?
| | Health Status | 1 | 2016 | 756 | 0.350 |
Why?
| | Telemedicine | 1 | 2019 | 792 | 0.350 |
Why?
| | Female | 17 | 2025 | 68650 | 0.330 |
Why?
| | Survival Rate | 4 | 2019 | 1870 | 0.330 |
Why?
| | Preoperative Period | 2 | 2020 | 116 | 0.320 |
Why?
| | Immunity, Innate | 2 | 2013 | 804 | 0.320 |
Why?
| | Adolescent | 11 | 2025 | 20409 | 0.320 |
Why?
| | B-Lymphocytes | 1 | 2013 | 816 | 0.290 |
Why?
| | Immunization Programs | 2 | 2021 | 213 | 0.270 |
Why?
| | Cohort Studies | 4 | 2024 | 5423 | 0.260 |
Why?
| | Risk Assessment | 4 | 2022 | 3255 | 0.250 |
Why?
| | Hypertension, Portal | 2 | 2017 | 61 | 0.240 |
Why?
| | Smartphone | 1 | 2025 | 87 | 0.220 |
Why?
| | Quality of Life | 1 | 2016 | 2694 | 0.220 |
Why?
| | Parents | 2 | 2025 | 1309 | 0.220 |
Why?
| | Vaccines, Combined | 1 | 2023 | 48 | 0.210 |
Why?
| | Hepatoblastoma | 1 | 2023 | 42 | 0.210 |
Why?
| | Chickenpox Vaccine | 1 | 2023 | 71 | 0.210 |
Why?
| | Health Care Surveys | 1 | 2025 | 557 | 0.210 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 106 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1491 | 0.200 |
Why?
| | Alagille Syndrome | 1 | 2022 | 33 | 0.200 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 48 | 0.190 |
Why?
| | Adenoviridae | 1 | 2023 | 190 | 0.190 |
Why?
| | Health Care Costs | 1 | 2025 | 366 | 0.190 |
Why?
| | Immunity, Humoral | 2 | 2013 | 118 | 0.190 |
Why?
| | Sarcoma | 1 | 2023 | 175 | 0.180 |
Why?
| | Incidence | 2 | 2019 | 2643 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2025 | 869 | 0.180 |
Why?
| | Age Factors | 2 | 2019 | 3150 | 0.170 |
Why?
| | Malnutrition | 1 | 2021 | 79 | 0.170 |
Why?
| | Evoked Potentials, Motor | 1 | 2020 | 40 | 0.170 |
Why?
| | Sarcopenia | 1 | 2021 | 74 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2013 | 372 | 0.170 |
Why?
| | Prednisolone | 1 | 2020 | 82 | 0.170 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2020 | 57 | 0.170 |
Why?
| | Wrist Joint | 1 | 2020 | 63 | 0.160 |
Why?
| | Polymerase Chain Reaction | 1 | 2023 | 1031 | 0.160 |
Why?
| | Remission Induction | 1 | 2020 | 274 | 0.160 |
Why?
| | Functional Laterality | 1 | 2020 | 220 | 0.160 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4891 | 0.160 |
Why?
| | Vaccination Refusal | 1 | 2020 | 70 | 0.150 |
Why?
| | Postoperative Period | 1 | 2020 | 329 | 0.150 |
Why?
| | Liver Neoplasms | 1 | 2023 | 635 | 0.150 |
Why?
| | Prognosis | 2 | 2017 | 3772 | 0.150 |
Why?
| | Movement | 1 | 2020 | 266 | 0.150 |
Why?
| | Electromyography | 1 | 2020 | 379 | 0.150 |
Why?
| | Early Diagnosis | 1 | 2019 | 234 | 0.140 |
Why?
| | Morbidity | 1 | 2019 | 300 | 0.140 |
Why?
| | Immunization, Secondary | 1 | 2018 | 87 | 0.140 |
Why?
| | Treatment Refusal | 1 | 2018 | 89 | 0.140 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 439 | 0.130 |
Why?
| | Transplantation Immunology | 1 | 2017 | 34 | 0.130 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2017 | 24 | 0.130 |
Why?
| | Palivizumab | 1 | 2016 | 13 | 0.130 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 290 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 566 | 0.130 |
Why?
| | Guideline Adherence | 1 | 2020 | 526 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 422 | 0.120 |
Why?
| | Enterostomy | 1 | 2015 | 5 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 583 | 0.120 |
Why?
| | Liver Failure | 1 | 2016 | 91 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 18 | 0.120 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 79 | 0.120 |
Why?
| | Failure to Thrive | 1 | 2015 | 29 | 0.120 |
Why?
| | Cholangitis | 1 | 2015 | 20 | 0.120 |
Why?
| | Canada | 1 | 2016 | 353 | 0.120 |
Why?
| | Preoperative Care | 1 | 2017 | 337 | 0.110 |
Why?
| | Liver | 4 | 2023 | 1836 | 0.110 |
Why?
| | Attitude to Health | 1 | 2018 | 432 | 0.110 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 110 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1500 | 0.110 |
Why?
| | Qualitative Research | 1 | 2020 | 1231 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 151 | 0.100 |
Why?
| | Constriction, Pathologic | 2 | 2025 | 234 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1102 | 0.100 |
Why?
| | Survivors | 1 | 2016 | 461 | 0.100 |
Why?
| | Th1 Cells | 1 | 2013 | 137 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 715 | 0.100 |
Why?
| | Logistic Models | 1 | 2017 | 1983 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1950 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1422 | 0.090 |
Why?
| | Sex Factors | 1 | 2017 | 1966 | 0.090 |
Why?
| | Portoenterostomy, Hepatic | 2 | 2023 | 45 | 0.090 |
Why?
| | Immunity, Cellular | 1 | 2012 | 265 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 1997 | 0.090 |
Why?
| | Antibody Formation | 2 | 2022 | 291 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 3968 | 0.080 |
Why?
| | Risk Factors | 2 | 2025 | 9779 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2013 | 1158 | 0.080 |
Why?
| | Antibodies, Viral | 2 | 2024 | 602 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1510 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4073 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2697 | 0.060 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1891 | 0.050 |
Why?
| | Stakeholder Participation | 1 | 2024 | 74 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 19 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 26 | 0.050 |
Why?
| | Adult | 1 | 2025 | 35505 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 154 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 398 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 125 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 263 | 0.050 |
Why?
| | North America | 1 | 2022 | 294 | 0.040 |
Why?
| | Horses | 1 | 2021 | 107 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 281 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 2021 | 186 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 206 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 193 | 0.040 |
Why?
| | Mice | 2 | 2013 | 16973 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 328 | 0.040 |
Why?
| | Animals | 3 | 2021 | 35334 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2017 | 16 | 0.030 |
Why?
| | Family Relations | 1 | 2017 | 87 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2023 | 3383 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 350 | 0.030 |
Why?
| | Bile Ducts | 1 | 2013 | 68 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 134 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2013 | 218 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4403 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2013 | 827 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7150 | 0.020 |
Why?
| | Virus Diseases | 1 | 2013 | 210 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1248 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2734 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 617 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2135 | 0.020 |
Why?
| | Autoimmunity | 1 | 2013 | 863 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6530 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2628 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2271 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 6412 | 0.010 |
Why?
|
|
Feldman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|